Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
Trackers› Clinical trials› New York
Clinical trial register · United States · industry-sponsored

Clinical Trials in New York, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9140 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 20 Oct 2026, 03:16 UTC
9140
Studies in scope
industry-sponsored, all four open statuses
4969
Recruiting now
open to new participants
2198
Lead sponsors
across recruiting studies
Top states
California 33 Florida 25 Texas 22 New York 22 Michigan 17
Narrow the registerReset
Recruitment status
Phase
Target enrolment
to

Trials with a site in New York

22 of 9140 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
Bristol-Myers Squibb
Phase 2
260
California, Colorado, Georgia, Maryland, Massachusetts, Michigan, Minnesota, New York
2026-07-27
Recruiting
A Study of GEN1106 in Participants With Solid Tumors
NCT07416123Solid Tumors, Urothelial Carcinoma
Genmab
Phase 1
103
Connecticut, New York, South Carolina, Tennessee, Texas
2026-04-14
Recruiting
Zai Lab (Shanghai) Co., Ltd.
Phase 1
180
California, Connecticut, Florida, Missouri, New York, Virginia
2026-03-02
Recruiting
Incyte Corporation
Phase 1
280
California, Michigan, Nebraska, New York, Tennessee, Texas
2026-01-08
Recruiting
DualityBio Inc.
Phase 2
450
California, Colorado, Florida, Georgia, Maryland, Nebraska, New York, Oregon
2025-07-18
Recruiting
Zai Lab (Shanghai) Co., Ltd.
Phase 1/2
166
California, Illinois, Michigan, New York, Ohio, Pennsylvania, Tennessee, Texas
2025-05-12
Recruiting
Fortvita Biologics (USA)Inc.
Phase 1
285
Arizona, Florida, Minnesota, New York, Texas
2025-04-29
Recruiting
Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
NCT06915753Metastatic Hepatocellular Carcinoma, Solid Tumors, Solid Tumor, Adult, FGFR Gene Amplification
Tyra Biosciences, Inc
Phase 1
125
California, Kansas, Maryland, Massachusetts, Michigan, New York, Tennessee
2025-04-24
Recruiting
ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC
NCT06816992Solid Tumors, EGFR Exon 20 Insertion Mutations, NSCLC, EGFR-mutated NSCLC
ORIC Pharmaceuticals
Phase 1
76
New York, Virginia
2025-02-27
By invitation
Follow-Up for Study Participants Treated With an Allogeneic CAR T-Cell Product
NCT06925685Hematologic Malignancies, Solid Tumors
Allogene Therapeutics
Observational
50
New York
2025-01-31
Recruiting
Daiichi Sankyo
Phase 1
150
Massachusetts, New York, Tennessee
2024-11-14
Recruiting
GlaxoSmithKline
Phase 1
675
Alabama, California, Florida, Kansas, Massachusetts, Michigan, Minnesota, New York
2024-07-02
Recruiting
Quanta Therapeutics
Phase 1
250
California, Colorado, Connecticut, Florida, New York, North Carolina, Oklahoma, Tennessee
2024-02-05
Recruiting
Incyte Corporation
Phase 1
710
Arizona, California, Colorado, Florida, Maryland, Massachusetts, New Jersey, New York
2024-01-04
Recruiting
Incyte Corporation
Phase 1
570
California, Massachusetts, Michigan, New Jersey, New York, Pennsylvania, Rhode Island, Texas
2023-07-24
Recruiting
Pfizer
Phase 4
210
Arizona, Georgia, Massachusetts, Minnesota, Missouri, New Jersey, New York, North Carolina
2022-07-05
Active, closed
Incyte Corporation
Phase 1
291
California, Colorado, Connecticut, Florida, Georgia, New York, North Carolina, Pennsylvania
2022-07-05
Recruiting
ORIC Pharmaceuticals
Phase 1/2
350
California, Connecticut, District of Columbia, Florida, Illinois, Massachusetts, Minnesota, New York
2022-03-10
Recruiting
Spectrum Pharmaceuticals, Inc
Phase 2
40
New York, North Carolina, Ohio, Texas
2021-05-20
Active, closed
Genentech, Inc.
Phase 1
123
Connecticut, Michigan, New York, Tennessee, Texas
2018-06-06
Active, closed
ModernaTX, Inc.
Phase 1
161
California, District of Columbia, Florida, Massachusetts, New York, Ohio, Pennsylvania, Texas
2017-08-14
Active, closed
Hoffmann-La Roche
Phase 1/2
69
California, Colorado, Georgia, Illinois, Maryland, Massachusetts, Missouri, New York
2016-05-03
Rows per page Showing 1–22 of 22
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 20 October 2026. https://priyalifescience.com/clinical-trials-usa/state/new-york

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,140 studies in total at the last sync on 20 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 22 of those studies with a site in New York that also match the filters currently applied.

How many clinical trials are recruiting in New York?

17 of the 22 studies on this page are recruiting new participants as of the 20 Oct 2026, 03:16 UTC sync. A further 0 have not yet opened recruitment, 4 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (New York), 22 studies
PhaseStudiesRecruitingShare
Phase 1141163.6%
Phase 1/23213.6%
Phase 23313.6%
Observational104.5%
Phase 4114.5%

Most active sponsors

Lead sponsors with the most studies (New York)
Lead sponsorStudiesRecruiting
Incyte Corporation43
ORIC Pharmaceuticals22
Zai Lab (Shanghai) Co., Ltd.22
Allogene Therapeutics10
Bristol-Myers Squibb11
Daiichi Sankyo11
DualityBio Inc.11
Fortvita Biologics (USA)Inc.11
Genentech, Inc.10
Genmab11
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.